The report has been developed as a part of IHE’s partnership in the VINNOVA-funded innovation milieu Test Bed Sweden Precision Health Cancer.

A Public-Private Partnership focusing on implementation of precision health in cancer in Sweden is under establishment. SweConnect will be project managed by Vision Zero Cancer in collaboration with Genomic Medicine Sweden (GMS).

Implementation of precision cancer medicine and economic evaluation for Health Technology Assessment (HTA) – what are the challenges and how do we address them?

Testbed Sweden for Precision Health in Cancer is a system demonstrator of how to introduce concrete precision medicine activities into the Swedish healthcare system in a way that is sustainable and just.

In 2021, Vision Zero Cancer, Genomic Medicine Sweden (GMS) and SciLifeLab joined forces with public sector authorities, regions, healthcare, academia, industry and patient associations to create an innovation hub that facilitates the introduction of more precise prevention and treatment in cancer care.

Testbed Sweden Precision Health Cancer is a national collaborative project for the design and method development of precision medicine treatment studies

Vision Zero Cancer and Genomic Medicine Sweden (GMS) join forces with SciLifeLab, public sector authorities, regions, healthcare, academia, industry and patient associations to create an innovation milieu that facilitates the introduction of more precise prevention and treatment in cancer care.

One size fits all is no longer applicable. Precision medicine has made several advancements in recent years. Rapid development in research and technology is creating conditions for a transformation of the system. With these developments come challenges and consequences – but which ones?